Truist initiated coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $14 price target Fulcrum Therapeutics has shown early signs that pociredir could be competitive in the SCD therapeutic landscape, the analyst tells investors in a research note. Encouraging data from the phase Ib PIONEER study for pociredir shows notable induction of HbF, most recently in patients dosed with 12 mg of drug, which in July showed robust and clinically meaningful absolute mean fetal hemoglobin HbF induction of 8.6% from baseline at 12 weeks, and safety continues to remain in-line with previous dosing cohorts and healthy volunteer data, the firm says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
- Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors
- Fulcrum’s pociredir shows promising early efficacy vs. mitapivat, says Leerink
- Oppenheimer not surprised by Agios data, continues to favor Fulcrum approach
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls